Lactobacillus reuteri

Phase 3Biologic

TTulane University School of Medicine

Lactobacillus reuteri is one of 122 biologic programs targeting Androgenetic Alopecia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenetic AlopeciaActive, not recruiting

Necrotizing EnterocolitisActive, not recruiting

Chronic PeriodontitisActive, not recruiting

Chronic ConstipationActive, not recruiting

Oral MucositisActive, not recruiting

Androgenetic AlopeciaPhase 2

Active, not recruiting

Necrotizing EnterocolitisPhase 3

Active, not recruiting

Chronic PeriodontitisPreclinical

Active, not recruiting

Chronic ConstipationPhase 3

Active, not recruiting

Oral MucositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Duragesic

CCephalon

Phase 3

2 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Bactroban

PPadagis LLC

Phase 3

1 7

Benadryl

PParkedale

Phase 3

1 8

Curcumin

Merck & Co.

Phase 3

2 9

Lactobacillus reuteri

TTulane University School of Medicine

Phase 3

2 10

N-Acetyl Cyteien

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Androgenetic Alopecia

NCT07370519

Clinical

Trials by Indication[1]

Children2 trials

Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months

Completed·TTulane University School of Medicine·Phase 1·NCT02460575·60 enrolled

Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru

Completed·TTulane University School of Medicine·Phase 1·NCT02124122·60 enrolled

Chronic Periodontitis2 trials

The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis

Completed·TTanta University·Phase 1·NCT04697199·12 enrolled

Antibiotic and Probiotic Therapies in the Adjuvant Treatment of the Chronic Periodontitis.

Completed·UUniversidade Estadual Paulista Júlio de Mesquita Filho·N/A·NCT03692819·45 enrolled

Oral Mucositis2 trials

Effects of Probiotics in Preventing Oral Mucositis

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT03552458·50 enrolled

Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors

Completed·WWest China Hospital·Phase 2·NCT06285591·160 enrolled

Inflammation1 trial

Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic

Completed·TThe University of Texas Health Science Center, Houston·Phase 1·NCT01849991·21 enrolled

Necrotizing Enterocolitis1 trial

Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants

Completed·ZZekai Tahir Burak Women's Health Research and Education Hospital·Phase 3·NCT01531179·400 enrolled

3 more indications

Chronic constipation1 trial

Lactobacillus Reuteri in Adult With Functional Chronic Constipation

Completed·—·Phase 3·NCT01870700·40 enrolled

Androgenetic Alopecia1 trial

Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia

Not yet recruiting·SShenzhen People's Hospital·Phase 2·NCT07370519·388 enrolled

Unspecified1 trial

Safety of Lactobacillus Reuteri in Healthy Volunteers

Completed·TTulane University School of Medicine·Phase 1·NCT00774163·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lactobacillus reuteri. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactobacillus reuteri compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactobacillus reuteri. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tulane University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: TTulane University School of Medicine

Lactobacillus reuteri

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Children2 trials

Chronic Periodontitis2 trials

Oral Mucositis2 trials

Inflammation1 trial

Necrotizing Enterocolitis1 trial

Chronic constipation1 trial

Androgenetic Alopecia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News